[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR125406A1 - Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen - Google Patents

Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen

Info

Publication number
AR125406A1
AR125406A1 ARP220101045A ARP220101045A AR125406A1 AR 125406 A1 AR125406 A1 AR 125406A1 AR P220101045 A ARP220101045 A AR P220101045A AR P220101045 A ARP220101045 A AR P220101045A AR 125406 A1 AR125406 A1 AR 125406A1
Authority
AR
Argentina
Prior art keywords
peptide
acid sequence
protein
gnpa
seq
Prior art date
Application number
ARP220101045A
Other languages
English (en)
Inventor
Joshua Joyner Sims
Yuan Yuan
James M Wilson
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of AR125406A1 publication Critical patent/AR125406A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan en el presente documento composiciones que incluyen péptidos de unión a los capilares cerebrales y/o que atraviesan la barrera hematoencefálica (BBB), vinculados a estos o insertos en una proteína selectiva de un vector recombinante que tiene al menos un péptido exógeno que comprende una secuencia de aminoácidos de Y-G/A/R/K-Y/H-GNPA-T/R/HRYFD-V/K. Se proporcionan composiciones que proporcionan dichos conjugados, péptidos selectivos o vectores recombinantes que tienen una cápside mutante o proteína de envoltura, así como usos de estos. Reivindicación 1: Una partícula de virus adenoasociado recombinante (rAAV) caracterizada porque comprende: (a) una cápside de AAV que comprende proteína VP1, proteínas VP2 y proteínas VP3, donde la proteína VP3 tiene una secuencia de aminoácidos que comprende una región hipervariable que comprende un péptido de direccionamiento exógeno que tiene la secuencia: conector de N-terminal opcional- Y-X’-X’’-GNPA-X’’’-RYFD-X’’’’, donde X’ es G, A, R, K, X’’ es Y o H, X’’’ es T, R o H, y X’’’’ es V o K (SEQ ID Nº 14) - conector de C-terminal opcional; y (b) un genoma vectorial empaquetado en la cápside de AAV, donde el genoma vectorial comprende una secuencia de ácidos nucleicos que codifica un producto génico bajo el control de secuencias que direccionan la expresión de este. Reivindicación 10: Un péptido de direccionamiento a células cerebrales recombinante, el péptido caracterizado porque comprende un motivo dirigido al núcleo de una secuencia de aminoácidos de Y-X’-X’’-GNPA-X’’’-RYFD-X’’’’, donde X’ es G, A, R, K, X’’ es Y o H, X’’’ es T, R o H, y X’’’’ es V o K (SEQ ID Nº 14), opcionalmente flanqueada en el amino terminal y/o en el carboxi terminal de la SEQ ID Nº 14 por dos aminoácidos a siete aminoácidos, y opcionalmente el péptido o péptido con conectores está conjugado con una nanopartícula, una segunda molécula o una proteína de cápside viral recombinante. Reivindicación 21: Un método para aumentar la transducción de células de producción de AAV in vitro caracterizado porque comprende transducir células con una secuencia de ácidos nucleicos que codifica una cápside de AAV que comprende un péptido de direccionamiento exógeno de Y-X’-X’’-GNPA-X’’’-RYFD-X’’’’, donde X’ es G, A, R, K, X’’ es Y o H, X’’’ es T, R o H, y X’’’’ es V o K (SEQ ID Nº 14) motivo del núcleo.
ARP220101045A 2021-04-23 2022-04-22 Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen AR125406A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163178881P 2021-04-23 2021-04-23

Publications (1)

Publication Number Publication Date
AR125406A1 true AR125406A1 (es) 2023-07-12

Family

ID=81585505

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101045A AR125406A1 (es) 2021-04-23 2022-04-22 Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen

Country Status (10)

Country Link
US (1) US20240207452A1 (es)
EP (1) EP4334334A1 (es)
AR (1) AR125406A1 (es)
AU (1) AU2022262771A1 (es)
BR (1) BR112023021971A2 (es)
CA (1) CA3216004A1 (es)
CO (1) CO2023014723A2 (es)
MX (1) MX2023012513A (es)
TW (1) TW202305124A (es)
WO (1) WO2022226263A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210148232A (ko) 2019-04-01 2021-12-07 테나야 테라퓨틱스, 인코포레이티드 조작된 캡시드를 갖는 아데노-연관 바이러스
WO2024130070A2 (en) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
TW202440939A (zh) 2022-12-17 2024-10-16 賓州大學委員會 具心臟及骨骼肌特異性靶向模體的重組aav突變載體及含有其之組成物
CN116693633B (zh) * 2023-02-21 2023-12-22 广州派真生物技术有限公司 腺相关病毒突变体及其应用
WO2024229389A1 (en) * 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
TW202444917A (zh) * 2023-05-04 2024-11-16 美商航海家醫療公司 Ａａｖ衣殼變異體及其用途
TW202516019A (zh) 2023-06-29 2025-04-16 賓州大學委員會 具中樞神經系統靶向模體的突變aav及含有其之組成物
WO2025035143A1 (en) 2023-08-10 2025-02-13 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of spinal muscular atrophy
WO2025106661A1 (en) 2023-11-14 2025-05-22 The Trustees Of The University Of Pennsylvania Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof
WO2025129157A1 (en) 2023-12-15 2025-06-19 The Trustees Of The University Of Pennsylvania Gene therapy for treatment of canavan disease

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08506144A (ja) 1993-02-05 1996-07-02 ラポート グループ オーストラリア リミティド スラグ脱泡複合材料
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
PL310327A1 (en) 1993-02-12 1995-12-11 Univ Leland Stanford Junior Adjustable transcription of target genes and other biological processes
US20020173474A1 (en) 1993-02-12 2002-11-21 President And Fellows Of Harvard College Methods & materials involving dimerization-mediated regulation of biological events
US6972193B1 (en) 1993-02-12 2005-12-06 Board Of Trustees Of Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US6063625A (en) 1993-02-12 2000-05-16 Board Of Trustees Of Leland S, Stanford, Jr. University Regulated transcription of targeted genes and other biological events
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
US6492106B1 (en) 1994-06-27 2002-12-10 The Johns Hopkins University Mammalian proteins that bind to FKBP12 in a rapamycin-dependent fashion
US6476200B1 (en) 1994-06-27 2002-11-05 The Johns Hopkins University Mammalian proteins that bind to FKBP12 in a rapamycin-dependent fashion
WO1996006097A1 (en) 1994-08-18 1996-02-29 Ariad Gene Therapeutics, Inc. New multimerizing agents
US6133456A (en) 1994-08-18 2000-10-17 Ariad Gene Therapeutics, Inc. Synthetic multimerizing agents
US6150527A (en) 1994-08-18 2000-11-21 Ariad Pharmaceuticals, Inc. Synthetic multimerizing agents
ATE544776T1 (de) 1994-12-29 2012-02-15 Massachusetts Inst Technology Chimäre dna-bindeproteine
US6326166B1 (en) 1995-12-29 2001-12-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
WO1996041865A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
US6506379B1 (en) 1995-06-07 2003-01-14 Ariad Gene Therapeutics, Inc. Intramuscular delivery of recombinant AAV
DE69739853D1 (de) 1996-02-28 2010-06-02 Ariad Pharma Inc Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen
US6723531B2 (en) 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
CA2300376A1 (en) 1997-08-26 1999-03-04 Ariad Gene Therapeutics, Inc. Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain
US6479653B1 (en) 1997-08-26 2002-11-12 Ariad Gene Therapeutics, Inc. Compositions and method for regulation of transcription
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
JP2001514007A (ja) 1997-08-27 2001-09-11 アリアド ジーン セラピューティクス インコーポレイテッド キメラ転写アクチベーター、ならびにそれに関連する組成物および使用
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
EP1045915A2 (en) 1998-01-15 2000-10-25 Ariad Gene Therapeutics, Inc. Regulation of biological events using multimeric chimeric proteins
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
CA2319492A1 (en) 1998-02-13 1999-08-19 President And Fellows Of Harvard College Novel dimerizing agents, their production and use
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
US6258603B1 (en) 1998-06-17 2001-07-10 Rohm And Haas Company Ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7109317B1 (en) 1998-11-06 2006-09-19 President And Fellows Of Harvard College FK506-based regulation of biological events
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
WO2001014387A1 (en) 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. 28-epirapalogs
AU2001249315A1 (en) 2000-03-22 2001-10-03 Rheogene, Inc. Ecdysone receptor-based inducible gene expression system
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
US7531326B2 (en) 2001-02-20 2009-05-12 Intrexon Corporation Chimeric retinoid X receptors and their use in a novel ecdysone receptor-based inducible gene expression system
PT1456346E (pt) 2001-02-20 2012-05-02 Intrexon Corp Novo sistema de expressão de genes induzido baseado no recetor de ecdisona / recetor x retinoide invertebrado
EP1373470B1 (en) 2001-02-20 2013-04-24 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
ES2390070T3 (es) 2001-02-20 2012-11-06 Intrexon Corporation Nuevos receptores mutantes de sustitución y su uso en un sistema de expresión génica inducible basado en receptores nucleares
CA2756866C (en) 2001-11-13 2017-06-06 The Trustees Of The University Of Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
ES2975413T3 (es) 2001-12-17 2024-07-05 Univ Pennsylvania Secuencias de serotipo 8 de virus adenoasociado (AAV), vectores que las contienen y usos de las mismas
DK2292780T3 (en) 2003-09-30 2017-12-04 Univ Pennsylvania Clades and sequences of adeno-associated virus (AAV), vectors containing them, and uses thereof
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
EP2359865B1 (en) 2005-04-07 2013-10-02 The Trustees of The University of Pennsylvania Method of increasing the function of an AAV vector
WO2006132118A1 (ja) 2005-06-09 2006-12-14 Matsushita Electric Industrial Co., Ltd. 振幅誤差補償装置及び直交度誤差補償装置
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
CN102245559B (zh) 2008-11-07 2015-05-27 麻省理工学院 氨基醇类脂质和其用途
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
SG10201908848RA (en) 2010-03-29 2019-10-30 Univ Pennsylvania Pharmacologically induced transgene ablation system
WO2011127255A1 (en) 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Preparation of lipid nanoparticles
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
US20140031418A1 (en) 2011-04-20 2014-01-30 The Trustees Of The University Of Pennsylvania Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens
SI2714752T1 (en) 2011-05-27 2018-03-30 Amicus Therapeutics, Inc. Methods for combining target peptides for recombinant lysosomal enzymes for improved treatment of lysosomal storage diseases
US20140206753A1 (en) 2011-06-08 2014-07-24 Shire Human Genetic Therapies, Inc. Lipid nanoparticle compositions and methods for mrna delivery
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
KR102087643B1 (ko) 2012-06-08 2020-03-11 에트리스 게엠베하 메신저 rna의 폐전달
WO2014089486A1 (en) 2012-12-07 2014-06-12 Shire Human Genetic Therapies, Inc. Lipidic nanoparticles for mrna delivering
JP6506250B2 (ja) 2013-03-15 2019-04-24 アミカス セラピューティックス インコーポレイテッド 化学架橋剤
JP6612214B2 (ja) * 2013-05-20 2019-11-27 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法
JP6486955B2 (ja) 2013-11-18 2019-03-20 アークトゥルス セラピューティクス， インコーポレイテッド Ｒｎａ送達のためのイオン化可能なカチオン性脂質
WO2015164778A1 (en) 2014-04-25 2015-10-29 The Trustees Of The University Of Pennysylvania Ldlr variants and their use in compositions for reducing cholesterol levels
SG10201902574RA (en) 2014-09-24 2019-04-29 Hope City Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
CA2985081A1 (en) 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-influenza antibodies and methods of use thereof
MX2018006840A (es) 2015-12-11 2019-03-28 California Inst Of Techn Focalizacion de peptidos para dirigir virus adenoasociados.
SG10201913833PA (en) 2017-02-28 2020-03-30 Univ Pennsylvania Influenza vaccines based on aav vectors
CN118956781A (zh) 2017-02-28 2024-11-15 宾夕法尼亚州大学信托人 腺相关病毒(aav)进化枝f载体及其用途
AU2019227726A1 (en) 2018-02-27 2020-09-10 The Trustees Of The University Of Pennsylvania Novel adeno-associated virus (AAV) vectors, aav vectors having reduced capsid deamidation and uses therefor
JP7660062B2 (ja) 2018-12-21 2025-04-10 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 導入遺伝子発現のｄｒｇ特異的低減のための組成物
US11867060B2 (en) 2019-02-04 2024-01-09 Technische Universität Wien Reinforced concrete tubbing segment
EP3976077A4 (en) 2019-04-29 2023-08-30 The Trustees of The University of Pennsylvania NEW AAV CAPSIDS AND COMPOSITIONS CONTAINING THEM
CN115175991A (zh) * 2019-10-16 2022-10-11 博德研究所 工程化肌肉靶向组合物
WO2021231579A1 (en) 2020-05-12 2021-11-18 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
MX2022016528A (es) 2020-06-17 2023-06-02 Univ Pennsylvania Composiciones y métodos para el tratamiento de pacientes de terapia génica.
TW202221127A (zh) 2020-08-14 2022-06-01 賓州大學委員會 新穎aav衣殼及含有其之組成物

Also Published As

Publication number Publication date
WO2022226263A1 (en) 2022-10-27
MX2023012513A (es) 2023-12-15
TW202305124A (zh) 2023-02-01
AU2022262771A9 (en) 2023-11-16
BR112023021971A2 (pt) 2024-02-20
CO2023014723A2 (es) 2023-11-20
CA3216004A1 (en) 2022-10-27
EP4334334A1 (en) 2024-03-13
US20240207452A1 (en) 2024-06-27
AU2022262771A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
AR125406A1 (es) Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen
CN112703198B (zh) 用于跨血脑屏障递送试剂的方法和组合物
AR124216A1 (es) Composiciones nuevas con motivos selectivos específicos del tejido y composiciones que las contienen
CN108699565B (zh) 用于定向腺相关病毒(aav)的靶向肽
US20240197918A1 (en) Tissue-targeted modified aav capsids and methods of use thereof
JP2022551487A (ja) 改変されたａａｖカプシドおよびその使用
IL317938A (en) Recombinant viral vectors with altered tropism and their uses for the targeted introduction of genetic material into human cells
KR20220009389A (ko) 엑소좀 및 aav 의 조성물
JP2021514659A (ja) Ａａｖキメラ
WO2019169144A1 (en) A modular system for gene and protein delivery based on aav
WO2022232327A9 (en) Aav capsids and uses thereof
JP2023511501A (ja) 新規の細胞内送達方法
KR102811229B1 (ko) 재조합 핵산 구조물
CN111718418A (zh) 一种增强基因编辑的融合蛋白及其应用
JPWO2022119871A5 (es)
ES2273277T3 (es) Peptidos moduladores de la actividad del factor de transcripcion engrailed.
AR131385A1 (es) Vectores mutantes de aav recombinantes con motivos de direccionamiento específicos de músculo cardíaco y esquelético y composiciones que contienen los mismos
KR20220024847A (ko) 포유류 세포에서 비천연 아미노산 혼입을 위한 향상된 플랫폼
US20230175013A1 (en) Controlled modification of adeno-associated virus (aav) for enhanced gene therapy
TWI845133B (zh) 胜肽介導的活性劑遞送
WO2024017387A1 (en) Novel aav capsids for targeting nervous system and uses thereof
WO2024238321A1 (en) Compositions and methods for targeted epigenetic modification
WO2024254232A2 (en) Two-plasmid system for aav vector particle production
WO2025038031A1 (en) Engineered mitochondrion
AR130546A1 (es) Tratamiento de la miocardiopatía arritmogénica con vectores de genoterapia con aav